A difficult to treat brain tumor that occurs at the same rate in dogs, as it does in humans, will be the subject of canine clinical trials at the Vet School at Virginia Tech.
Glioblastomas are rapidly growing brain tumors, which typically affect older adults. They’re notoriously difficult to remove and hard to treat because they quickly develop resistance to chemotherapy.
The main drug used to fight them is known as T-M-Z. Scientists from Virginia Tech and Carilion Clinic did a study in which they added another drug to the mix called ACT 1.
That combination appears to reduce resistance. But they're not yet entirely sure how it works. Finding those answers could lead to help for people suffering, not only from this, deadliest kind of brain tumor, but other types of tumors as well. Canine clinical trials will begin early net year, funded by National Institutes of Health. It covers all costs for treatment of dogs in the study, which comes to about twenty thousand dollars.
For details about the clinical trials, to take place at the Virginia Maryland School of Veterinary Medicine, click here.